natgillin/translations-raw huggingface dataset:
Patients with HIV-1 expressing three or more thymidine analogue associated mutations (TAMs) that included either an M41L or an L210W substitution in RT showed reduced susceptibility to tenofovir disoproxil fumarate.
Bolniki, pri katerih je HIV-1 izražal tri ali več mutacij povezanih z analogom timidina (TAM - thymidine- analogue associated mutations), ki so vsebovale mutacijo M41L ali L210W reverzne transkriptaze, so kazali zmanjšano občutljivost za zdravljenje s dizoproksiltenofovirijevim fumaratom.
Patients with HIV-1 harbouring mutations
Bolniki, okuženi s HIV–1, ki so nosilci mutacij
patients with HIV-1 RNA < 200 copies/ml
bolniki s HIV-1 RNA < 200 kopij/ml
patients with HIV-1 RNA < 50 copies/ml
bolniki s HIV-1 RNA < 50 kopij/ml
Patients with homocystinuria cannot convert homocysteine into cysteine, so homocysteine builds up in the blood and urine.
Pri bolnikih s homocistinurijo pretvorba homocisteina v cistein ne poteka, zato se homocistein kopiči v krvi in urinu.
Patients with human anti-mouse antibody or human anti-chimeric antibody (HAMA/HACA) titres may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.
Bolniki s prisotnimi humanimi protimišjimi protitelesi (HAMA) ali humanimi protihimernimi protitelesi (HACA) imajo lahko alergijske ali preobčutljivostne reakcije, če jih zdravimo z drugimi diagnostičnimi ali terapevtskimi monoklonskimi protitelesi.
Patients with hyperbilirubinaemia had higher concentrations for total SN-38 (see section 5.2) and therefore the risk of neutropenia is increased.
Bolniki s hiperbilirubinemijo so imeli povišane koncentracije skupnega SN-38 (glejte poglavje 5.2), zato je tveganje za nevtropenijo povečano.
Patients with hyperprolinaemia.
Bolniki s hiperprolinemijo.
Patients with hypertension
pri bolnikih s hipertenzijo,
Patients with hypocalcaemia (see section 4.4).
Bolniki s hipokalciemijo (glejte poglavje 4.4).
Patients with hypophosphatasia do not have enough normally functioning ALP, which leads to weak bones.
Bolniki s hipofosfatazijo nimajo dovolj normalno delujoče ALP, kar povzroča šibke kosti.
Patients with immunodeficiencies.
Bolniki z oslabljenim imunskim sistemom.
Patients with impaired hepatic function
Bolniki z okvaro jeter
Patients with impaired kidney function
Bolniki z okvarjenim delovanjem ledvic
Patients with impaired renal function
Bolniki z okvaro ledvic
Patients with impaired renal function should be more carefully monitored with respect to the development of anaemia.
Pri bolnikih z okvarjeno ledvično funkcijo je potrebno bolj skrbno spremljanje, da ugotovite morebiten nastanek anemije.
Patients with impairment of liver function,
Bolniki z okvarjenim delovanjem jeter.
Patients with impairment of liver function.
Bolniki z okvarjenim delovanjem jeter.
Patients with inadequate liver function (National Cancer Institute – Common Terminology Criteria for Adverse Events Grade 3 liver function tests (AST, ALT > 5 x ULN for > 2 weeks; bilirubin > 3 x ULN) and renal function (CrCl < 30 mL/min) were excluded.
Bolniki z nezadostnim delovanjem jeter (jetrni testi 3. stopnje po National Cancer Institute – Common Terminology Criteria for Adverse Events (AST, ALT > 5 x ZNM (“zgornje normalne meje”) > 2 tedna; bilirubin > 3 x ZNM) in delovanjem ledvic (očistek kreatinina < 30 ml/min) so bili izključeni.
Patients with inadequate response to prior therapy*
Bolniki z nezadostnim odzivom na predhodno zdravljenje
Patients with inborn AIDS (Acquired Immunodeficiency Syndrome) and recurrent infections.
Bolniki s prirojenim AIDS-om (sindrom pridobljene imunske pomanjkljivosti) in ponavljajočimi se okužbami.
Patients with increased bleeding risk (such as thrombocytopenia) and muscle disease (such as myositis), must not be treated in view of the large number of intramuscular injections required.
Bolniki s povečanim tveganjem za krvavitev (kot je trombocitopenija) in mišično boleznijo (kot je miozitis) se ne smejo zdraviti, saj je potrebno veliko število intramuskularnih injiciranj.
Patients with increased hepatic enzymes during anidulafungin therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing anidulafungin therapy.
Bolnike, pri katerih se med zdravljenjem z anidulafunginom pojavi zvišana raven jetrnih encimov, je treba nadzirati glede znakov slabšanja delovanja jeter; oceniti je treba koristi in tveganja nadaljnjega zdravljenja z anidulafunginom.
Patients with increased risk for opportunistic infections, including immunocompromised patients (including those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies (see sections 4.4 and 4.8).
Bolniki, pri katerih je povečano tveganje oportunističnih okužb, vključno z bolniki z oslabljenim imunskim sistemom (vključno s tistimi, ki so nedavno prejemali terapijo za zaviranje imunskega odziva ali tisti z oslabljenim imunskim sistemom zaradi prejšnjega zdravljenja) (glejte poglavji 4.4 in 4.8).
Patients with increased risk for opportunistic infections, including immunocompromised patients (including those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies).
Bolniki s povečanim tveganjem za oportunistične okužbe, vključno z bolniki z oslabljenim imunskim odzivom (tudi bolniki, ki v tem času prejemajo imunosupresivna zdravila ali imajo oslabljen imunski odziv zaradi predhodnega zdravljenja).
Patients with increases in AST, ALT and alkaline phosphatase between cycles may necessitate dose reduction (see section 4.2).
Pri bolnikih s povečanjem AST, ALT in alkalne fosfataze med cikli je morda potrebno zmanjšati odmerek (glejte poglavje 4.2).
Patients with inhibitors
Sjúklingar með mótefni
Patients with intracranial pathology; neoplasm or evidence of cerebral herniation
Bolniki z intrakranialnim obolenjem; novotvorbo ali znaki herniacije možganov
Patients with kidney disease
Ledvična bolezen.
Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical studies, and use in these patients is not recommended.
Bolniki z znano dedno degenerativno okvaro očesne mrežnice, vključno z retinitis pigmentosa, niso bili vključeni v klinične študije, zato se uporaba pri njih ne priporoča.
Patients with known hypersensitivity to other bisphosphonates
Bolniki z znano preobčutljivostjo za druge difosfonate
Patients with known IgE mediated hypersensitivity to obinutuzumab must not be treated (see section 4.3).
Bolnikov, ki imajo znano, z IgE posredovano preobčutljivost za obinutuzumab, se z njim ne sme zdraviti (glejte poglavje 4.3).
Patients with known or suspected sphincter of Oddi disease or dysfunction and/or biliary tract or pancreatic disease, including a history of pancreatitis, and those who have had a cholecystectomy or are missing a gallbladder due to other reasons must not receive this medicinal product (see section 4.3).
Bolniki z znano ali domnevno boleznijo ali nepravilnim delovanjem Oddijevega sfinktra in/ali boleznijo žolčnih poti ali trebušne slinavke, vključno z anamnezo pankreatitisa, in tisti, ki so imeli holecistektomijo ali nimajo žolčnika zaradi drugih razlogov, ne smejo prejeti tega zdravila (glejte poglavje 4.3).
Patients with known risk factors for thromboembolism – including prior thrombosis – should be closely monitored.
Bolnike z znanimi dejavniki tveganja za trombembolijo, vključno s predhodno trombozo, je treba skrbno nadzirati.
Patients with known risk factors for thromboembolism – including prior thrombosis – should be closely monitored.
Bolnike z znanimi dejavniki tveganja za tromboembolijo – vključno s predhodno trombozo – je treba natančno spremljati.
Patients with known risk factors – including prior thrombosis – should be closely monitored, and action should be taken to try to minimize all modifiable risk factors (eg. smoking, hypertension, and hyperlipidaemia).
Bolnike z znanimi dejavniki tveganja, vključno s predhodnimi trombozami, je potrebno skrbno spremljati in z ustreznimi ukrepi poskusiti zmanjšati tiste dejavnike tveganja, na katere lahko vplivamo (npr. kajenje, hipertenzija in hiperlipidemija).
Patients with lamivudine-resistant chronic hepatitis B: No new adverse reactions to tenofovir disoproxil fumarate were identified from a randomised, double-blind study (GS-US-174-0121) in which 280 lamivudine-resistant patients received treatment with tenofovir disoproxil fumarate (n = 141) or emtricitabine/tenofovir disoproxil fumarate (n = 139) for 240 weeks.
Bolniki s kroničnim hepatitisom B, rezistentnim na lamivudin: Novih neželenih učinkov na dizoproksiltenofovirijev fumarat v randomizirani, dvojno slepi študiji (GS-US-174-0121), v kateri je 280 na lamivudin rezistentnih bolnikov 240 tednov prejemalo zdravljenje z dizoproksiltenofovirijevim fumaratom (n = 141) ali emtricitabinom/dizoproksiltenofovirijevim fumaratom (n = 139), niso opredelili.
Patients with left ventricular outflow obstruction (e.g. aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be particularly sensitive to the actions of vasodilators including avanafil.
Bolniki z obstrukcijo iztočnega trakta levega prekata (npr. aortno stenozo ali idiopatsko hipertrofično subaortno stenozo) in bolniki s hudo okvaro avtonomnega uravnavanja krvnega tlaka so lahko še posebej občutljivi za delovanje vazodilatatorjev, tudi za avanafil.
Patients with left ventricular outflow obstruction, e.g., aortic stenosis and idiopathic hypertrophic subaortic stenosis, can be sensitive to the action of vasodilators including Type 5 phosphodiesterase inhibitors.
Bolniki z obstrukcijo iztisa levega prekata, npr. aortno stenozo in idiopatsko hipertrofično subaortno stenozo, so lahko občutljivi za delovanje vazodilatatorjev, tudi za zaviralce fosfodiesteraze tipa 5.
Patients with life-threatening arrhythmias
bolniki z življenjsko ogrožujočimi aritmijami,
Patients with liver and lung toxicity related to the previous use of amiodarone
Bolniki s toksičnimi učinki na jetra ali pljuča, povezanimi s predhodno uporabo amiodarona.
Patients with liver disease
Bolnice z boleznijo jeter
Patients with liver impairment
Bolniki z okvaro jeter
Patients with liver problems
Bolniki z jetrnimi težavami
Patients with liver problems or
Bolniki z jetrnimi obolenji ali resnimi motnjami v delovanju ledvic naj
Patients with liver problems or severe
Bolniki z jetrnimi obolenji ali resnimi motnjami v delovanju
Patients with liver problems or severe kidney problems should start treatment on the 5 mg dose.
Bolniki z jetrnimi obolenji ali resnimi motnjami v delovanju ledvic morajo začeti zdravljenje s 5-miligramskim odmerkom.
Patients with liver problems or severe kidney problems should start treatment with the 25 mg dose.
Bolniki z jetrnimi obolenji ali resnimi motnjami v delovanju ledvic naj začnejo zdravljenje s 25-miligramskim odmerkom.
patients with liver problems, patients with pathological changes in their red blood cells (homozygous sickle cell anaemia).
bolniki s težavami z jetri, bolniki s patološkimi spremembami rdečih krvničk (homozigotna anemija srpastih celic).
Patients with liver/kidney problems:
Bolniki s težavami z jetri ali ledvicami:
Patients with low albumin levels (≤ 35 g/L) or MELD ≥ 10 had a twofold greater risk of TEEs than those with higher albumin levels; those aged ≥ 60 years had a 2-fold greater risk of TEEs compared to younger patients.
Pri bolnikih z nizko vrednostjo albuminov (≤ 35 g/L) ali z oceno po MELD ≥ 10 je bilo tveganje za pojav trombemboličnih dogodkov dvakrat večje, kot pri tistih z višjimi vrednostmi albuminov; tveganje za pojav trombemboličnih dogodkov je bilo dvakrat večje pri bolnikih starih ≥ 60 let kot pri mlajših bolnikih.
Patients with low antibody production following transplantation of bone marrow cells from another person.
Bolniki z majhnim nastajanjem protiteles po presaditvi celic kostnega mozga druge osebe.
Patients with low body weight (<60 kg) had a higher incidence of PPE, proteinuria, of Grade 3 or 4 hypocalcaemia and hyponatraemia, and a trend towards a higher incidence of Grade 3 or 4 decreased appetite.
Bolniki z majhno telesno maso (<60 kg) so imeli večjo incidenco PPE, proteinurije, hipokalciemije in hiponatriemije stopnje 3 ali 4 in nagnjenost k večji incidenci zmanjšanega apetita stopnje 3 ali 4.
Patients with low expression levels of UGT1A1 or genetic glucuronidation disorders (e.g.
Bolniki z majhnim izražanjem UGT1A1 ali genetskimi motnjami glukuronidacije (npr.
Patients with low levels of this protein have excessive activity of these two systems, which leads to the symptoms of angioedema.
Pri bolnikih z nizkimi ravnmi te beljakovine ta dva sistema prekomerno delujeta, kar povzroči simptome angioedema.
Patients with low tumour burden (< 50%) responded best to BLINCYTO treatment with CR/CRh* rate of 72.9% (CI 59.7 – 83.6).
Bolniki z majhnim tumorskim bremenom (< 50 %) so se na zdravljenje z zdravilom BLINCYTO odzvali najbolje in so imeli delež CR/CRh* 72,9 % (IZ 59,7-83,6).
Patients with low weight ( 60 kg) (see sections 4.2, 4.8, and 5.2).
Bolniki z majhno telesno maso ( 60 kg) (glejte poglavja 4.2, 4.8 in 5.2).
Patients with malabsorption may not adequately absorb vitamin D3.
Absorpcija vitamina D3 pri bolnikih z malabsorpcijo lahko ni zadostna.
Patients with maximal
Bolniki z največjo
Patients with MDRH&R-TB
bolniki z MDRH&R-TB
Patients with measurable disease
bolniki z merljivo boleznijo
Patients with melanoma driven by BRAF mutations other than V600E were excluded from the confirmatory trial and with respect to patients with the V600K mutation in single arm studies the activity appears lower than in V600E tumours.
Bolniki z melanomom, ki ga vodijo druge mutacije BRAF, in ne V600E, so bili izključeni iz potrditvenega preskušanja in študije z enim krakom so pri bolnikih z mutacijo V600K pokazale manjšo aktivnost kot pri tumorjih V600E.
patients with metastatic carcinoma of the ovary after failure of first line or subsequent therapy. patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1).
bolnikih z metastatskim karcinomom jajčnikov po neuspehu z zdravili prvega ali naslednjega izbora bolnikih z relapsom drobnoceličnega pljučnega raka, pri katerih ponovno zdravljenje s terapijo prve izbire ni primerno (glejte poglavje 5.1).
patients with metastatic carcinoma of the ovary after failure of first line or subsequent therapy. patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1).
bolnikih z metastatskim karcinomom jajčnikov po neuspehu z zdravili prvega ali naslednjega izbora. bolnikih z relapsom drobnoceličnega pljučnega raka, pri katerih ponovno zdravljenje s terapijo prve izbire ni primerno (glejte poglavje 5.1).
patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1).
bolnicah z rakom jajčnika z metastazami, če terapija prve izbire in tudi naslednje terapije niso uspele. bolnikih z relapsom drobnoceličnega pljučnega raka, pri katerih ponovno zdravljenje s terapijo prve izbire ni primerno (glejte poglavje 5.1).
patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1).
bolnicah z rakom jajčnika z metastazami, če terapija prve izbire in tudi naslednje terapije niso uspele. bolnikih z relapsom drobnoceličnega pljučnega raka, pri katerih ponovno zdravljenje s terapijo prve izbire ni primerno (glejte poglavje 5.1).
Patients with methaemoglobinaemia due to chlorate poisoning
Bolniki z methemoglobinemijo zaradi zastrupitve s kloratom.
Patients with microbiologically confirmed invasive candidiasis (MITT population) and neutropenia were identified in an analysis of pooled data from 4 similarly designed prospective, open-label, non- comparative studies.
V analizi združenih podatkov iz 4 prospektivnih, odprtih, neprimerjalnih študij s podobnim načrtom so ocenili bolnike z mikrobiološko potrjeno invazivno kandidozo (populacija MITT) in nevtropenijo.
Patients with mild and moderate renal impairment (creatinine clearance 60­90 ml/min and 30–
Bolniki z blago ali zmerno okvaro ledvic (očistek kreatinina 60-90 ml/min oz.
Patients with mild and moderate renal impairment had at steady state an average 1.8-fold and 3.6-fold higher pre-dosedabigatran plasma concentrations compared with patients with CrCL > 80 mL/min, respectively.
Bolniki z blago in zmerno ledvično okvaro so imeli v ravnotežnem stanju pred odmerkom povprečno 1,8- oziroma 3,6-krat večje koncentracije dabigatrana v plazmi kot tisti s CrCl > 80 ml/min.
Patients with mild or moderate impairment of liver function should be started at a lower dose.
Bolniki z blažjo ali zmerno okvaro delovanja jeter morajo zdravljenje začeti z nižjim odmerkom.
Patients with mild or moderate infusion reaction may receive ipilimumab with close monitoring.
Bolniki z blago ali zmerno infuzijsko reakcijo lahko prejmejo ipilimumab ob skrbnem nadziranju.
Patients with mild or moderate kidney problems, including some elderly patients, should also start with a lower dose of Invega, but the medicine is not recommended for patients with severe kidney problems.
Bolniki z blažjimi ali zmernimi težavami z ledvicami, vključno z nekaterimi skupinami starostnikov, morajo zdravljenje prav tako začeti z nižjim odmerkom zdravila Invega, medtem ko zdravilo za bolnike s hudimi težavami z ledvicami ni priporočljivo.
patients with mild or moderate renal impairment (creatinine clearance between 31 and 90 ml/min; see section 4.4) activated partial thromboplastin time (aPTT) should be monitored.
Pri bolnikih z blago ali zmerno okvaro ledvic (očistek kreatinina med 31 in 90 ml/min, glejte poglavje 4.4) je treba kontrolirati aktivirani parcialni tromboplastinski čas (aPTČ).
Patients with mild or moderately reduced liver function should not receive doses higher than 40 mg a day
Bolniki z blago do zmerno okvaro delovanja ledvic ne smejo prejemati odmerkov, višjih od 40 mg na dan.
Patients with mild or moderately reduced liver function should not receive doses higher than 40 mg a day.
Bolniki z blago do zmerno okvaro delovanja ledvic ne smejo prejemati odmerkov, višjih od 40 mg na dan.
Patients with mild renal impairment did not have a clinically meaningful increase in the plasma concentration of sitagliptin as compared to normal healthy control subjects.
V primerjavi z zdravimi kontrolnimi osebami pri bolnikih z blago ledvično okvaro plazemske koncentracije sitagliptina niso bile klinično pomembno povečane.
Patients with mild renal impairment did not have a clinically meaningful increase in the plasma concentration of sitagliptin as compared to normal healthy control subjects.
V primerjavi z zdravimi kontrolnimi osebami pri bolnikih z blago ledvično okvaro plazemske koncentracije sitagliptina niso bile pomembno povečane.
Patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min) should avoid taking non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, and aspirin (> 1.3 g daily) for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.5).
Bolniki z blagim do zmernim popuščanjem delovanja ledvic (očistek kreatinina od 45 do 79 ml/min) naj se izogibajo jemanju nesteroidnih protivnetnih zdravil (NSAID), denimo, ibuprofena in acetilsalicilne kisline (> 1,3 g dnevno) 2 dni pred dajanjem pemetrekseda, na dan dajanja in še 2 dni po dajanju pemetrekseda (glejte poglavje 4.5).
Patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min) should avoid taking non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, and aspirin (> 1.3 g daily) for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.5).
Bolniki z blagim do zmernim popuščanjem delovanja ledvic (očistek kreatinina od 45 do 79 ml/min) naj se izogibajo jemanju nesteroidnih protivnetnih zdravil (NSAIDs – non steroidal anti-inflammatory drugs), kot sta ibuprofen in acetilsalicilna kislina (> 1,3 g dnevno) 2 dni pred dajanjem pemetrekseda, na dan dajanja in še 2 dni po dajanju pemetrekseda (glejte poglavje 4.5).
Patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min) should avoid taking non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, and aspirin (> 1.3 g daily) for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.5).
Bolniki z blago do zmerno ledvično insuficienco (očistek kreatinina od 45 do 79 ml/min) se morajo izogibati jemanju nesteroidnih protivnetnih zdravil (NSAID), kot je ibuprofen in acetilsalicilna kislina (> 1,3 g dnevno) 2 dni pred dajanjem pemetrekseda, na dan dajanja in še 2 dni po dajanju pemetrekseda (glejte poglavje 4.5).
Patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min) should avoid taking non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, and aspirin (> 1.3 g daily) for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.5).
Bolniki z blagim do zmernim popuščanjem delovanja ledvic (očistek kreatinina od 45 do 79 ml/min) naj se izogibajo jemanju nesteroidnih protivnetnih zdravil (NSAID), denimo, ibuprofena in acetilsalicilne kisline (> 1,3 g dnevno) 2 dni pred dajanjem pemetrekseda, na dan dajanja in še 2 dni po dajanju pemetrekseda (glejte poglavje 4.5).
Patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min) should avoid taking non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, and aspirin (>1.3 g daily) for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.5).
Bolniki z blagim do zmernim popuščanjem delovanja ledvic (očistek kreatinina od 45 do 79 ml/min) naj se izogibajo jemanju nesteroidnih protivnetnih zdravil (NSAID), denimo, ibuprofena in acetilsalicilne kisline (> 1,3 g dnevno) 2 dni pred dajanjem pemetrekseda, na dan dajanja in še 2 dni po dajanju pemetrekseda (glejte poglavje 4.5).
Patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min) should avoid taking non-steroidal anti-inflammatory medicinal product (NSAIDs) such as ibuprofen, and aspirin (> 1.3 g daily) for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.5).
Bolniki z blagim do zmernim popuščanjem delovanja ledvic (očistek kreatinina od 45 do 79 ml/min) naj se izogibajo jemanju nesteroidnih protivnetnih zdravil (NSAIDs – non steroidal anti-inflammatory drugs), kot sta ibuprofen in acetilsalicilna kislina (> 1,3 g dnevno) 2 dni pred dajanjem pemetrekseda, na dan dajanja in še 2 dni po dajanju pemetrekseda (glejte poglavje 4.5).
Patients with mild–to–moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of indinavir resulting in approximately 60 % higher mean AUC following a 400–mg dose.
Pri bolnikih z blago do zmerno jetrno okvaro in kliničnimi znaki ciroze je bila presnova indinavirja zmanjšana, kar je povzročilo približno 60 % višjo povprečno vrednost AUC po 400 mg odmerku.
Patients with mild–to–moderate hepatic insufficiency due to cirrhosis will require a dose reduction of indinavir due to decreased metabolism of indinavir (see section 4.2).
Bolnikom z blago do zmerno jetrno okvaro zaradi ciroze je treba zmanjšati odmerek indinavirja zaradi zmanjšane presnove indinavirja (glejte poglavje 4.2).
Patients with missing cirrhosis status were excluded from this subgroup analysis.
Bolniki brez statusa ciroze so bili izključeni iz te analize podskupin.
Patients with moderate hepatic impairment (Child Pugh B) showed a higher exposure to this medicine (see section 5.2).
Pri bolnikih z zmerno okvaro jeter (Child Pugh B) je bila izpostavljenost temu zdravilu večja (glejte poglavje 5.2).